New drug TAK-280 aims to fight advanced cancers that resist standard care
NCT ID NCT05220098
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests an experimental drug called TAK-280 in people with advanced cancer that cannot be removed by surgery or has spread to other parts of the body, and who have not responded to or cannot tolerate standard treatments. The main goals are to check the drug's safety and how well it works. Participants receive TAK-280 through an IV for up to 14 cycles, each lasting 28 days, and are followed for about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-280
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced cancers that no longer respond to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Cabrini Health
Malvern, 3144, Australia
-
Centre Hospitalier Universitaire de Sherbrooke CHUS
Sherbrooke, J1H 5N4, Canada
-
Centre Intégré de Cancérologie du CHU de Québec - Université Laval
Québec, G1J 1Z4, Canada
-
Chris O'Brien Lifehouse Hospital
Camperdown, New South Wales, 2050, Australia
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Quironsalud Barcelona, NEXT Oncology
Barcelona, 08023, Spain
-
Hospital Universitari Dexeus - Grupo Quironsalud
Barcelona, 08028, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, 08035, Spain
-
Monash Medical Centre
Clayton, 3168, Australia
-
SCRI Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
-
START MADRID_Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Sanford Cancer Center
Sioux Falls, South Dakota, 57104-8805, United States
-
Southern Oncology Clinical Research Unit
Bedford Park, 5042, Australia
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195-0001, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Arkansas For Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Minnesota - Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States